NGM BIOPHARMACEUTICALS INC (NGM) Forecast, Price Target & Analyst Ratings

NASDAQ:NGM • US62921N1054

Current stock price

1.54 USD
-0.02 (-1.28%)
At close:
1.55 USD
+0.01 (+0.65%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NGM BIOPHARMACEUTICALS INC (NGM).

Forecast Snapshot

Consensus Price Target

Price Target
$1.70
+ 10.11% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 2, 2024
Period
Q1 / 2024
EPS Estimate
-$0.46
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
49.09%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$1.70
Upside
+ 10.11%
From current price of $1.54 to mean target of $1.70, Based on 11 analyst forecasts
Low
$1.57
Median
$1.58
High
$2.10

Price Target Revisions

1 Month
-60.88%
3 Months
-60.88%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for NGM. The average price target is 1.7 USD. This implies a price increase of 10.11% is expected in the next year compared to the current price of 1.54.
The average price target has been revised downward by 60.88% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

NGM Current Analyst RatingNGM Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

NGM Historical Analyst RatingsNGM Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
49.09%
NGM was analyzed by 11 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about NGM.
In the last month the buy percentage fell by 26 points. So the trust of analysts is decreasing.
NGM was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2024-03-12Raymond JamesDowngrade Outperform -> Market Perform
2024-02-28TD CowenDowngrade Outperform -> Market Perform
2023-11-22B. Riley SecuritiesMaintains Buy -> Buy
2023-05-03CitigroupInitiate Buy
2023-03-30B. Riley SecuritiesMaintains Buy
2022-11-04Raymond JamesMaintains Outperform
2022-10-18Cowen & Co.Maintains Outperform
2022-10-18Raymond JamesDowngrade Strong Buy -> Outperform
2022-10-18Goldman SachsDowngrade Buy -> Neutral
2022-10-17Piper SandlerDowngrade Overweight -> Neutral
2022-10-17JefferiesDowngrade Buy -> Hold
2022-10-07B. Riley SecuritiesMaintains Buy
2022-07-20JefferiesInitiate Buy
2022-05-24Goldman SachsMaintains Buy
2021-11-05Raymond JamesMaintains Strong Buy
2021-09-17BMO CapitalMaintains Outperform
2021-09-13Raymond JamesUpgrade Outperform -> Strong Buy
2021-08-06Raymond JamesMaintains Outperform
2021-05-24Raymond JamesDowngrade Strong Buy -> Outperform
2021-03-05Chardan CapitalMaintains Buy
2021-03-05Raymond JamesMaintains Strong Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 2, 2024
Period
Q1 / 2024
EPS Estimate
-$0.46
Revenue Estimate
Revenue Q2Q
-100.00%
EPS Q2Q
19.90%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
-100.00%
Revenue (3 Months)
-100.00%
EPS (1 Month)
-27.96%
EPS (3 Months)
-27.96%

Next Earnings Summary

NGM is expected to report earnings on 5/2/2024. The consensus EPS estimate for the next earnings is -0.46 USD and the consensus revenue estimate is 0 USD.
The next earnings revenue estimate has been revised downward by 100% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2024 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
NGM revenue by date.NGM revenue by date.
77.9M
-10.87%		55.3M
-29.01%		4.417M
-92.01%
-100.00%		36.036M17.242M
-52.15%		67.744M
292.90%		236.12M
248.55%		357.81M
51.54%
EBITDA
YoY % growth
NGM ebitda by date.NGM ebitda by date.
-114.61M
-17.86%		-162.16M
-41.49%		-149.242M
7.97%		-162.008M
-8.55%		-168.2M
-3.82%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
NGM ebit by date.NGM ebit by date.
-120.7M
-16.28%		-166.2M
-37.70%		-151.463M
8.87%		-128.369M
15.25%		-127.729M
0.50%		-104.545M
18.15%		-88.592M
15.26%		-43.749M
50.62%		96.61M
320.83%		191.75M
98.48%
Operating Margin
NGM operating margin by date.NGM operating margin by date.
-154.94%-300.54%-3,429.09%N/AN/A-290.11%-513.81%-64.58%40.92%53.59%
EPS
YoY % growth
NGM eps by date.NGM eps by date.
-1.56
-4.70%		-2.05
-31.41%		-1.72
16.10%		-1.21
29.44%		-0.95
21.40%		-1.03
-8.01%		-1.03-1.03-0.43
57.84%		0.15
134.88%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.46
19.90%		-0.29
36.33%		-0.23
33.63%		-0.19
41.85%
Revenue
Q2Q % growth
-100.00%
-100.00%
-100.00%
-100.00%
EBITDA
Q2Q % growth		-31.008M
37.46%		-32.767M
16.86%		-34.469M
-17.52%		N/A
EBIT
Q2Q % growth		-49.148M
2.08%		-44.246M
-9.03%		-34.684M
-11.78%		-29.421M
0.81%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

NGM Yearly Revenue VS EstimatesNGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2028 2029 2030 100M 200M 300M
NGM Yearly EPS VS EstimatesNGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
11.90%
EPS Next 5 Year
6.98%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
94.76%
Revenue Next 5 Year
69.25%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

NGM BIOPHARMACEUTICALS INC / NGM Forecast FAQ

What is the average price target for NGM BIOPHARMACEUTICALS INC (NGM) stock?

11 analysts have analysed NGM and the average price target is 1.7 USD. This implies a price increase of 10.11% is expected in the next year compared to the current price of 1.54.

What is the next earnings date for NGM stock?

NGM BIOPHARMACEUTICALS INC (NGM) will report earnings on 2024-05-02, after the market close.

Can you provide the consensus estimates for NGM BIOPHARMACEUTICALS INC next earnings?

The consensus EPS estimate for the next earnings of NGM BIOPHARMACEUTICALS INC (NGM) is -0.46 USD and the consensus revenue estimate is 0 USD.

Can you provide the analyst count for NGM BIOPHARMACEUTICALS INC stock?

The number of analysts covering NGM BIOPHARMACEUTICALS INC (NGM) is 11.